none of the approved immunomodulatory drugs in adults multiple sclerosis (ms) patients have been officially approved for the pediatric patients and are currently used off-label in this population. in this study, we evaluated the effectiveness and tolerability of intramuscular interferon beta1-a (avonex®) and subcutaneously injected interferon beta1-b (betaferon®) in children with definite relap...

A population-based retrospective chart review of the biochemical liver tests of 844 patients with multiple sclerosis prescribed a beta-interferon (IFNbeta) product in British Columbia, Canada was performed between 1995 and 2001. Overall, 36.9% (243/659) of patients developed new elevations of alanine aminotransferase. All the IFNbetas caused elevated aminotransferase levels compared with pretre...

OBJECTIVE To determine the efficacy and tolerability of subcutaneous Interferon beta 1a (IFNbeta-1a) among Iraqi patients with relapsing remitting multiple sclerosis (RRMS). METHODS The study was held at the Multiple Sclerosis clinic at Baghdad Teaching Hospital, Baghdad, Iraq from January-October 2004. Thirty-seven patients with clinically definite RRMS and disability status scale below 6.5 ...

objective(s): in the present study, c57bl/6 female mice (n=56) were used to explore the neuroprotective effects of riboflavin in motor disability of experimental autoimmune encephalomyelitis (eae) as a model of multiple sclerosis. materials and methods: the animals were assigned into 7 groups: sham-operated 1 (so1), healthy mice receiving pbs (phosphate buffer saline); sham-operated 2 (so2), he...

OBJECTIVE To assess the efficacy of interferon beta (IFN beta) in combination with methotrexate in treatment of patients with rheumatoid arthritis. METHODS 209 patients with active rheumatoid arthritis, who had been on methotrexate for at least six months and at a stable dose for four weeks before study entry, were randomised in double blind fashion to receive placebo (0.05 ml or 0.5 ml), IFN...

background:  multiple  sclerosis  (ms) patients permanently confronted  with serious challenges from treatment regimen. developing  a new  questionnaire in ms management, through  evaluation  of patients’ perspectives   and  knowledge   regarding   treatment  will help  to  identify the  sources  of tension, and  to  build  a therapeutic   alliance.   we   purposed   to   describe    ms patient...

INTRODUCTION Cutaneous adverse events (AEs) have been observed in clinical studies of daclizumab high-yield process (HYP) in relapsing-remitting multiple sclerosis (RRMS). Here, we report cutaneous AEs observed in the randomized, double-blind, active-comparator DECIDE study (ClinicalTrials.gov identifier, NCT01064401). METHODS DECIDE was a randomized, double-blind, active-controlled phase 3 s...

AIM To study pattern-reversal visual evoked potentials (VEP) in patients with relapsing-remitting multiple sclerosis on interferon beta-1a treatment. METHODS In a randomized, prospective, non-blinded, placebo-uncontrolled study, VEP were studied in 9 patients (18 eyes) with relapsing-remitting multiple sclerosis treated with interferon. Three of them have had an episode of unilateral optic ne...